{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:41:12Z","timestamp":1762443672815},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Berichtet wird \u00fcber eine 46-j\u00e4hrige Patientin, die seit ihrer fr\u00fchen Kindheit unter einer schweren atopischen Dermatitis leidet und seit ihrem 18.\u00a0Lebensjahr unter einer Alopecia areata totalis, die mittlerweile in eine Alopecia areata universalis \u00fcbergegangen ist. Durch die Einleitung einer Therapie mit dem monoklonalen Antik\u00f6rper Dupilumab wurde erneutes Haarwachstum am Kapillitium, im Gesicht und an den Unterschenkeln beobachtet. Dupilumab blockiert die \u03b1\u2011Untereinheit des IL(Interleukin)-4-Rezeptors, unterbindet die Signalkaskade von IL\u20114 und IL-13 und f\u00fchrt so zu einer reduzierten Th2-Immunantwort. Die schwere Auspr\u00e4gung der Ekzeme und der Juckreiz mit Ein- und Durchschlafst\u00f6rungen sind bereits 14\u00a0Tage nach Beginn der Einnahme zur\u00fcckgegangen. Die Patientin vertr\u00e4gt das Medikament ohne wesentliche Nebenwirkungen, ihre Lebensqualit\u00e4t ist deutlich verbessert. Patienten mit einer schweren atopischen Dermatitis und einer Alopecia areata k\u00f6nnten von Dupilumab in Zukunft doppelt profitieren.<\/jats:p>","DOI":"10.1007\/s00105-021-04898-y","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:20:11Z","timestamp":1633479611000},"page":"556-559","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis"],"prefix":"10.1007","volume":"73","author":[{"given":"L.","family":"Reinhold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lindhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Homey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Firouzi-Memarpuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"4898_CR1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson\u00a0EL, Bieber\u00a0T, Guttman-Yassky\u00a0E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N\u00a0Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"issue":"1","key":"4898_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla\u00a0LC et\u00a0al (2018) Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J\u00a0Am Acad Dermatol 78(1):1\u201312","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4898_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev\u00a0SA et\u00a0al (2014) Lifetime incidence risk of alopecia areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990\u20132009. J\u00a0Invest Dermatol 134(4):1141\u20131142","journal-title":"J Invest Dermatol"},{"issue":"11","key":"4898_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamadermatol.2018.2976","volume":"154","author":"LR Penzi","year":"2018","unstructured":"Penzi\u00a0LR et al (2018) Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol 154(11):1358\u20131360","journal-title":"JAMA Dermatol"},{"key":"4898_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jdcr.2018.11.006","volume":"5","author":"DT Alniemi","year":"2019","unstructured":"Alniemi\u00a0DT, McGevna\u00a0L (2019) Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis. JAAD Case Rep 5:111\u2013112","journal-title":"JAAD Case Rep"},{"key":"4898_CR6","series-title":"NCT number: NCT03570749","volume-title":"A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1)","author":"Eli Lilly and Company","year":"2018","unstructured":"Eli Lilly and Company (2018) A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1). NCT number: NCT03570749"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:12:01Z","timestamp":1657019521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["4898"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04898-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"15 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Reinhold, K.\u00a0Lange, H.\u00a0Lindhof, B.\u00a0Homey und P.\u00a0Firouzi-Memarpuri geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}